- List
- By Topic
- On Map
- Search Details

"Adenocarcinoma of lung"
Need help? See RSS Feeds
Choose a feed type:

"Adenocarcinoma of lung" (321 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02804646 | Recruiting | Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma |
|
|
Interventional | Phase 4 |
|
Other |
|
|
100 | All | 18 Years to 75 Years (Adult, Senior) | NCT02804646 | 20160606 | June 2016 | December 2017 | December 2018 | June 17, 2016 | June 21, 2016 |
|
||
2 | NCT02493582 | Active, not recruiting | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR |
|
|
Interventional | Phase 2 |
|
Other |
|
|
400 | All | 18 Years to 70 Years (Adult, Senior) | NCT02493582 | CAA | July 2015 | July 2030 | July 2033 | July 9, 2015 | February 5, 2016 | |||
3 | NCT03371381 | Recruiting | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
170 | All | 18 Years and older (Adult, Senior) | NCT03371381 | CR108232 2016-002543-41 64041757LUC2002 |
December 18, 2017 | October 13, 2020 | May 19, 2023 | December 13, 2017 | April 17, 2018 |
|
||
4 | NCT03090815 | Recruiting | Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma |
|
|
Observational |
|
Other |
|
|
100 | All | 18 Years to 80 Years (Adult, Senior) | NCT03090815 | HKU_UW_16_104 | February 2016 | December 2017 | December 2017 | March 27, 2017 | March 27, 2017 |
|
|||
5 | NCT02843711 | Active, not recruiting | Molecular Analysis of 150 Lung Adenocarcinoma |
|
|
Observational |
|
Other |
|
|
152 | All | 18 Years to 99 Years (Adult, Senior) | NCT02843711 | 69HCL15_0161 | LUNG-EST | January 2014 | January 2016 | December 2017 | July 26, 2016 | July 26, 2016 |
|
||
6 | NCT01249066 | Unknown † | Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma |
|
Observational |
|
Other |
|
100 | All | 25 Years to 85 Years (Adult, Senior) | NCT01249066 | DMR99-IRB-096 | September 2010 | November 29, 2010 | November 29, 2010 |
|
|||||||
7 | NCT01482585 | Unknown † | Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy |
|
|
Observational |
|
Other |
|
|
200 | All | 20 Years and older (Adult, Senior) | NCT01482585 | SMC 2011-09-083 | October 2011 | July 2016 | December 2016 | November 30, 2011 | November 30, 2011 |
|
|||
8 | NCT03376737 | Recruiting | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
120 | All | 18 Years and older (Adult, Senior) | NCT03376737 | AHEAD-HNP012 | October 12, 2017 | June 2018 | June 2019 | December 18, 2017 | December 18, 2017 |
|
||
9 | NCT02980991 | Recruiting | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
80 | All | 18 Years to 75 Years (Adult, Senior) | NCT02980991 | PCPOII | December 2015 | January 2018 | April 2018 | December 2, 2016 | December 2, 2016 |
|
||
10 | NCT02898857 | Recruiting | Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma |
|
|
Observational |
|
Other |
|
|
18 | All | 18 Years to 75 Years (Adult, Senior) | NCT02898857 | 9758 | NOTCH | September 2016 | September 2017 | December 2017 | September 13, 2016 | September 13, 2016 |
|
||
11 | NCT01819428 | Terminated | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
22 | All | 20 Years and older (Adult, Senior) | NCT01819428 | NOV120101-201 | March 2013 | November 2015 | November 2015 | March 27, 2013 | March 1, 2016 |
|
||
12 | NCT02951637 | Not yet recruiting | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial |
|
|
Interventional | Phase 2 |
|
Other |
|
|
300 | All | 18 Years to 85 Years (Adult, Senior) | NCT02951637 | Chest004 | December 2016 | April 2018 | December 2019 | November 1, 2016 | November 1, 2016 | |||
13 | NCT02399566 | Not yet recruiting | Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma |
|
|
Interventional | Phase 4 |
|
Other |
|
|
300 | All | 18 Years to 75 Years (Adult, Senior) | NCT02399566 | CCTEBMTLA-2015 | May 2015 | January 2018 | January 2019 | March 26, 2015 | March 26, 2015 | |||
14 | NCT02621333 | Recruiting | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
280 | All | 18 Years to 75 Years (Adult, Senior) | NCT02621333 | HenanCH003 | October 2015 | September 2018 | September 2018 | December 3, 2015 | December 3, 2015 |
|
||
15 | NCT02691871 | Unknown † | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
20 | All | 18 Years to 65 Years (Adult) | NCT02691871 | Ahead-L301 | February 2016 | October 2016 | December 2016 | February 25, 2016 | February 25, 2016 | |||
16 | NCT01564329 | Unknown † | The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 70 Years (Adult, Senior) | NCT01564329 | sim-endo-201201 | March 2012 | April 2013 | July 2013 | March 27, 2012 | March 27, 2012 |
|
||
17 | NCT02946359 | Recruiting | A+C in Metastatic Lung Adenocarcinoma Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
60 | All | 18 Years to 70 Years (Adult, Senior) | NCT02946359 | CAMAR01 | July 2016 | October 2017 | July 2018 | October 27, 2016 | November 2, 2016 |
|
||
18 | NCT02093000 | Completed | A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma |
|
|
Observational |
|
Industry |
|
|
201 | All | 18 Years and older (Adult, Senior) | NCT02093000 | ML29261 | November 30, 2014 | January 31, 2018 | January 31, 2018 | March 20, 2014 | February 23, 2018 |
|
|||
19 | NCT02239432 | Unknown † | Telomere Biology in Early Adenocarcinoma of the Lung |
|
Observational |
|
Other |
|
|
100 | All | 18 Years to 90 Years (Adult, Senior) | NCT02239432 | 0067-14-MMC | September 2014 | September 2016 | September 2017 | September 12, 2014 | September 12, 2014 |
|
||||
20 | NCT02891733 | Recruiting | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas |
|
Observational |
|
Other |
|
|
400 | All | Child, Adult, Senior | NCT02891733 | NTS | NTS | March 6, 2017 | December 2017 | December 2017 | September 7, 2016 | September 8, 2017 |
|
|||
21 | NCT01218516 | Completed | A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
130 | All | 18 Years and older (Adult, Senior) | NCT01218516 | MORAb-003-009 | April 2011 | December 2012 | November 2013 | October 11, 2010 | June 20, 2016 |
|
||
22 | NCT00716456 | Completed Has Results |
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
21 | All | 18 Years and older (Adult, Senior) | NCT00716456 | 08-055 | July 2008 | May 2011 | May 2011 | July 16, 2008 | April 30, 2015 | April 30, 2015 |
|
|
23 | NCT03254004 | Not yet recruiting | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm |
|
|
Interventional | Phase 2 |
|
Other |
|
|
70 | All | 20 Years and older (Adult, Senior) | NCT03254004 | 2017-08-032 | January 1, 2018 | November 30, 2020 | November 30, 2021 | August 18, 2017 | November 30, 2017 | |||
24 | NCT00511485 | Completed | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
43 | All | 18 Years and older (Adult, Senior) | NCT00511485 | 8109-008 EC-FV-03 |
August 2007 | July 2009 | November 2009 | August 6, 2007 | February 27, 2015 | |||
25 | NCT02120807 | Recruiting | Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas |
|
|
Interventional | Phase 1 |
|
Other / NIH |
|
|
34 | All | 18 Years and older (Adult, Senior) | NCT02120807 | 13-063 | April 2014 | April 2018 | April 2018 | April 23, 2014 | July 19, 2017 |
|
||
26 | NCT01942629 | Unknown † | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas |
|
|
Observational |
|
Other |
|
|
300 | All | 18 Years to 75 Years (Adult, Senior) | NCT01942629 | 0298-13ctil | October 2013 | October 2015 | December 2015 | September 16, 2013 | September 16, 2013 | ||||
27 | NCT01578668 | Completed | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases |
|
|
Interventional | Phase 2 |
|
Other |
|
|
69 | All | 18 Years and older (Adult, Senior) | NCT01578668 | GZTO1201 | January 2012 | January 2015 | January 2015 | April 17, 2012 | January 26, 2015 |
|
||
28 | NCT01877083 | Active, not recruiting | Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT01877083 | E7080-G000-209 | April 2013 | February 2016 | September 2016 | June 13, 2013 | September 16, 2016 |
|
||
29 | NCT02466568 | Not yet recruiting | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT02466568 | MCC-18147 1504-1392 |
June 2018 | December 31, 2019 | December 31, 2020 | June 9, 2015 | March 29, 2018 |
|
||
30 | NCT02011997 | Not yet recruiting | Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion |
|
|
Interventional | Phase 3 |
|
Other |
|
|
500 | All | 20 Years to 79 Years (Adult, Senior) | NCT02011997 | FAH-GZU-001 | cVATS | December 2013 | December 2021 | December 2021 | December 16, 2013 | December 16, 2013 |
|
|
31 | NCT01249053 | Unknown † | Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma |
|
Observational |
|
Other |
|
100 | All | 25 Years to 85 Years (Adult, Senior) | NCT01249053 | DMR99-IRB-062 | August 2010 | November 29, 2010 | November 29, 2010 |
|
|||||||
32 | NCT03298763 | Not yet recruiting | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
46 | All | 18 Years and older (Adult, Senior) | NCT03298763 | UCL/14/0453 | TACTICAL | March 1, 2018 | March 1, 2020 | March 1, 2024 | October 2, 2017 | October 2, 2017 |
|
|
33 | NCT02738684 | Unknown † | A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test |
|
Observational |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT02738684 | pfnaegmt-023 | April 2016 | January 2018 | January 2018 | April 14, 2016 | April 14, 2016 | |||||
34 | NCT02132143 | Unknown † | Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2 |
|
|
Interventional | Not Applicable |
|
Other |
|
|
60 | All | 18 Years to 75 Years (Adult, Senior) | NCT02132143 | LH-2014-XW | January 2014 | January 2017 | January 2017 | May 7, 2014 | May 6, 2015 |
|
||
35 | NCT01561456 | Completed | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT01561456 | AXL-003 2011-002007-15 |
December 2011 | December 2013 | December 2013 | March 23, 2012 | December 5, 2013 |
|
||
36 | NCT02975752 | Completed | EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA |
|
|
Observational |
|
Other |
|
|
48 | All | 18 Years to 90 Years (Adult, Senior) | NCT02975752 | EGFRdelEx 19 KRAS Exon 2 | EGFRdelEx19 | March 2015 | June 2016 | November 2016 | November 29, 2016 | November 29, 2016 | |||
37 | NCT01014286 | Active, not recruiting | Lung Cancer Mutation Consortium Protocol |
|
Observational |
|
Other |
|
|
1100 | All | 18 Years and older (Adult, Senior) | NCT01014286 | 09-0756 | September 2009 | December 2018 | December 2018 | November 16, 2009 | August 30, 2017 |
|
||||
38 | NCT03486496 | Not yet recruiting New |
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation |
|
|
Interventional | Phase 2 |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT03486496 | CSWOF201801 | Geber | June 5, 2018 | June 1, 2019 | February 1, 2020 | April 3, 2018 | April 3, 2018 |
|
|
39 | NCT01578551 | Active, not recruiting | A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
60 | All | 18 Years to 100 Years (Adult, Senior) | NCT01578551 | J1188 NA_00052073 2P50CA058184-16 |
NA_00052073 | April 2012 | November 2015 | November 2019 | April 17, 2012 | October 13, 2016 |
|
|
40 | NCT01259089 | Active, not recruiting | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
43 | All | 18 Years and older (Adult, Senior) | NCT01259089 | NU 10L01 STU00038215 |
March 2011 | December 2019 | December 2020 | December 13, 2010 | January 11, 2018 |
|
||
41 | NCT02951897 | Recruiting | Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma |
|
|
Interventional | Not Applicable |
|
Other |
|
|
120 | All | 45 Years to 70 Years (Adult, Senior) | NCT02951897 | TMMU-DP-2016-4-25 | CTCs detection | April 2016 | December 2019 | December 2019 | November 1, 2016 | November 2, 2016 |
|
|
42 | NCT03361319 | Not yet recruiting | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
194 | All | 18 Years and older (Adult, Senior) | NCT03361319 | CCR 4448 | N3 | January 2018 | January 2022 | January 2022 | December 4, 2017 | December 4, 2017 | ||
43 | NCT03184571 | Recruiting | BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
48 | All | 18 Years and older (Adult, Senior) | NCT03184571 | BGBC008 MK-3475 PN531 2016-003609-32 |
October 17, 2017 | December 2018 | December 2019 | June 12, 2017 | November 17, 2017 |
|
||
44 | NCT03076164 | Recruiting | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT03076164 | 15-098 | March 1, 2017 | March 2019 | March 2019 | March 10, 2017 | August 28, 2017 |
|
||
45 | NCT02787447 | Recruiting | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy |
|
|
Interventional | Phase 2 |
|
Other |
|
|
46 | All | 18 Years to 75 Years (Adult, Senior) | NCT02787447 | HZCH-2016-09 | May 2016 | December 2017 | May 2020 | June 1, 2016 | November 25, 2016 |
|
||
46 | NCT03029065 | Not yet recruiting | Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal Metastasis |
|
Observational |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT03029065 | ShandongCHI004 | CSF | January 2017 | January 2018 | December 2018 | January 24, 2017 | January 24, 2017 | ||||
47 | NCT02276027 | Active, not recruiting | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
66 | All | 18 Years and older (Adult, Senior) | NCT02276027 | CINC280X2205 | January 20, 2015 | April 28, 2018 | April 28, 2018 | October 27, 2014 | September 14, 2017 |
|
||
48 | NCT00198380 | Completed | Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
90 | All | 18 Years and older (Adult, Senior) | NCT00198380 | IFCT-0401 | April 2005 | December 2008 | December 2009 | September 20, 2005 | April 30, 2010 |
|
||
49 | NCT03380468 | Recruiting | Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
300 | All | 18 Years to 70 Years (Adult, Senior) | NCT03380468 | Stage-1 | ACTPI | January 1, 2018 | January 1, 2021 | December 31, 2025 | December 21, 2017 | January 16, 2018 |
|
|
50 | NCT00456716 | Completed | Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
5 | All | 18 Years and older (Adult, Senior) | NCT00456716 | CRC 0639 | March 2007 | December 2008 | December 2008 | April 5, 2007 | March 4, 2010 |
|
† Study has passed its completion date and status has not been verified in more than two years.